A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use

F. Jonsson, Y. Ou, L. Claret, D. Siegel, S. Jagannath, R. Vij, A. Badros, S. Aggarwal, R. Bruno

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Change in tumor size estimated using longitudinal tumor growth inhibition (TGI) modeling is an early predictive biomarker of clinical outcomes for multiple cancer types. We present the application of TGI modeling for subjects with multiple myeloma (MM). Longitudinal time course changes in M-protein data from relapsed and/or refractory MM subjects who received single-agent carfilzomib in phase II studies (n=456) were fit to a TGI model. The tumor growth rate estimate was similar to that of other anti-myeloma agents, indicating that the model is robust and treatment-independent. An overall survival model was subsequently developed, which showed that early change in tumor size (ECTS) at week 4, Eastern Cooperative Oncology Group performance status (ECOG PS), hemoglobin, sex, percent bone marrow cell involvement, and number of prior regimens were significant independent predictors for overall survival (P < 0.001). ECTS based on M-protein modeling could be an early biomarker for survival in MM following exposure to single-agent carfilzomib.

Original languageEnglish
Pages (from-to)711-719
Number of pages9
JournalCPT: Pharmacometrics and Systems Pharmacology
Volume4
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Dive into the research topics of 'A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use'. Together they form a unique fingerprint.

Cite this